Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Pioglitazone/Metformin Combination Therapy in Subjects With Type 2 Diabetes Mellitus and Dyslipidemia.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes according to the American Diabetes Association Criteria.~* Treatment with individual maximal tolerated dose of metformin (850 - 2000 mg) as monotherapy within the last 12 weeks.~* Glycosylated Hemoglobin greater than or equal to 6.5% and less than or equal to 9%.~* Dyslipidemia defined as high-density lipoprotein cholesterol less than or equal to 1.03 mmol/l (40 mg/dL) and/or triglycerides greater than or equal to 1.7 mmol/l (150 mg/dL).~* Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study.~Exclusion Criteria:~* Type 1 diabetes mellitus.~* Insulin-dependent type 2 diabetes mellitus.~* Treatment or history of treatment with any insulin formulation other than emergency for more than 2 weeks.~* Treatment with other oral antidiabetic drugs in addition to metformin within the last 12 weeks.~* Anamnestic history of hypersensitivity to the study drugs or to drugs with similar chemical structures.~* Is required to take or intends to continue taking any disallowed medication, any prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication, including:~  * Heparin (and heparin-like drugs)~ * coumarin~ * phenprocoumon~ * hirudin~ * Protein C~ * Fondaparinux~ * antithrombin III~ * Peroxisome Proliferation Activating Receptor (gamma) agonists~ * Treatment within the last 12 weeks with:~    * fibrates~   * gemfibrozil~   * niacin~   * months~   * Rifampicin~ * Changes in dosage of any statin treatment to lower low-density lipoprotein within 2 weeks before study entry and during study participation interval.~ * Changes in dosage of any anticoagulant treatment with acetyl salicylic acid and/or clopidogrel within 2 weeks before study entry and during study participation interval.~ * Start of statin and/or anticoagulant treatment during study participation interval.~* History of severe or multiple allergies and/ or acute severe infections.~* Have had more than one unexplained episode of severe hypoglycemia (defined as requiring assistance of another person due to disabling hypoglycemia) within 6 months prior to screening visit.~* Progressive fatal disease.~* Any elective surgery during study participation.~* History of drug or alcohol abuse within the last 5 years.~* A history of significant cardiovascular (New York Heart Association stage I - IV), respiratory, gastrointestinal, hepatic (alanine aminotransferase and/or aspartate aminotransferase greater than 2.5 times the upper limit of the normal reference range), renal (serum creatinine greater than 1.2 mg/dL in women and greater than 1.5 mg/dL in men, glomerular filtration rate less than 60 ml/min as estimated by the Cockroft-Gault formula), neurological, psychiatric and/or hematological disease as judged by the investigator, history of macular edema.~* Blood donation within the last 30 days.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Pioglitazone 15 mg and Metformin 850 mg BID (Type: EXPERIMENTAL): None
- Glimepiride 2 mg and Metformin 850 mg BID (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).